

## Vitenskapelige publikasjoner

I 2016 hadde SESAM 40 publikasjoner i ulike tidsskrifter – 5 stk er nivå 2 publikasjoner

**Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG, Zetterberg H, Mollenhauer B, Boada M, Aarsland D; European DLB Consortium.**

Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia. *Movement Disorder*, 31(8), 1203-1208. Nivå 1

**Alme KN, Engelsen BA, Naik M, Naess H.**

Identifying patients at risk of acute symptomatic seizure after ischemic stroke. *Acta Neurologica Scandinavica*. [Epub ahead of print] Nivå 1

**Ballard C, Orrell M, Sun Y, Moniz-Cook E, Stafford J, Whitaker R, Woods B, Corbett A, Banerjee S, Testad I, Garrod L, Khan Z, Woodward-Carlton B, Wenborn J, Fossey J.**

Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELP - A factorial cluster randomised controlled trial. *International Journal of Geriatric Psychiatry*. Nivå 1

**Biundo R, Weis L, Bostantjopoulou S, Stefanova E, Falup-Pecurariu C, Kramberger MG, Geurtsen G, Antonini A, Weintraub D, Aarsland D.**

MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. *Journal of Neural Transmission*, 123(4), 431-438. Nivå 1

**Bjerkreim AT, Thomassen L, Waje-Andreasen U, Selvik HA, Naess H.**

Hospital Readmission after Intracerebral Hemorrhage. *Journal of Stroke and Cerebrovascular Diseases*, 25(1), 157-162. Nivå 1

**Breitve MH, Hynnen MJ, Brønnick K, Chwistek LJ, Auestad BH, Aarsland D, Rongve A.**

A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer's disease. *Alzheimer's research & therapy*, 8(3), 1. Nivå 2

**Bringeland GH, Nacu A, Waje-Andreasen U, Thomassen L, Naess H.**

U-curve relation between cholesterol and prior ischemic stroke. *Brain and Behavior*, 6(11):e00574. Nivå 1

**Brønnick K, Breitve MH, Rongve A, Aarsland D**

Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism. *Journal of Alzheimer's disease*, 53(4), 1277-1285. Nivå 1

**Chong JR, Chai YL, Lee JH, Howlett D, Attems J, Ballard CG, Aarsland D, Francis PT, Chen CP, Lai MK.**

Increased Transforming Growth Factor  $\beta$ 2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble  $\text{A}\beta$ 42 Load. *Journal of Alzheimer's disease* [Epub ahead of print]. Nivå 1

**Corbett A, Nunez KM, Smeaton E, Testad I, Thomas AJ, Closs SJ, Briggs M, Gjestsen MT, Lawrence V.**

The landscape of pain management in people with dementia living in care homes: A mixed methods study. *International Journal of Geriatric Psychiatry*, 31(12), 1354-1370. Nivå 1

**Enache D, Solomon A, Cavallin L, Kareholt I, Kramberger MG, Aarsland D, Kivipelto M, Eriksdotter M, Winblad B, Jelic V.**

CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. *Neurobiology of Aging*, 42, 124-31. Nivå 1

**Enache D, Fereshtehnejad SM, Kåreholt I, Cermakova P, Garcia-Ptacek S, Johnell K, Religa D, Jelic V, Winblad B, Ballard C, Aarsland D, Fastbom J, Eriksdotter M.**

Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. *Acta Psychiatrica Scandinavica*, 134(5), 430-440. Nivå 2

**Fromm A, Haaland OA, Naess H, Thomassen L, Waje-Andreassen U.**

Atherosclerosis in Trial of Org 10172 in Acute Stroke Treatment Subtypes among Young and Middle-Aged Stroke Patients: The Norwegian Stroke in the Young Study. *Journal of Stroke & Cerebrovascular Diseases*, 25(4). 825-30. Nivå 1

**Hessen E, Stav AL, Auning E, Selnes P, Blomsø L, Holmeide CE, Johansen KK, Eliassen CF, Reinvang I, Fladby T, Aarsland D.**

Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases. *Journal of Parkinson's Disease*, 6(2). 413-421. Nivå 1

**Kjosavik SR, Gillam MH, Roughead EE.**

Average duration of treatment with antidepressants among concession card holders in Australia. *The Australian and New Zealand journal of psychiatry*, 50(12), 1180-5. Nivå 1

**Nacu A, Bringeland GH, Khanevski A, Thomassen L, Waje-Andreassen U, Naess H.**

Early neurological worsening in acute ischaemic stroke patients. *Acta Neurologica Scandinavica*, 133(1). 25-29. Nivå 1

**Nacu A, Kvistad CE, Naess H, Øygarden H, Logallo N, Assmus J, Waje-Andreassen U, Kurz KD, Neckelmann G, Thomassen L.**

NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study): Randomized Controlled Contrast-Enhanced Sonothrombolysis in an Unselected Acute Ischemic Stroke Population. *Stroke*. [Epub ahead of print] Nivå 2

**Novotny V, Khanevski AN, Thomassen L, Waje-Andreassen U, Naess H.**

Time patterns in multiple acute cerebral infarcts. *International Journal of Stroke*. [Epub ahead of print] Nivå 1

**Novotny V, Thomassen L, Waje-Andreassen U, Naess H.**

Acute cerebral infarcts in multiple arterial territories associated with cardioembolism. *Acta Neurologica Scandinavica*. [Epub ahead of print] Nivå 1

**Oppedal K, Engan K, Eftestøl TC, Beyer MK, Aarsland D.**

Classifying Alzheimer's disease, Lewy body dementia, and normal controls using 3D texture analysis in magnetic resonance images. *Biomedical Signal Processing and Control*, 33 (Suppl), 19-29. Nivå 1

**Parrado-Fernández C, Sandebring-Matton A, Rodriguez-Rodriguez P, Aarsland D, Cedazo-Mínguez A.**

Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. Nivå 1

**Romi F, Naess H.**

Spinal Cord Infarction in Clinical Neurology: A Review of Characteristics and Long-Term Prognosis in Comparison to Cerebral Infarction. *European Neurology*, 76(3-4), 95-98. Nivå 1

**Rongve A, Ballard C, Aarsland D.**

Non-Alzheimer Dementias. *Journal of Geriatric Psychiatry and Neurology*, 29(5), 247-248. Nivå 1

**Rongve A, Soennesyn H, Skogseth R, Oesterhus R, Hortobagyi T, Ballard C, Auestad BH, Aarsland D.**  
Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. *BMJ open*, 6(2), e010357. Nivå 1

**Sand KM, Naess H, Nilsen RM, Thomassen L, Hoff JM.**

Less thrombolysis in posterior circulation infarction-a necessary evil? *Acta Neurologica Scandinavica*. Nivå 1

**Sand KM, Wilhelmsen G, Naess H, Midelfart A, Thomassen L, Hoff JM.**

Vision problems in ischaemic stroke patients: effects on life quality and disability.  
*European Journal of Neurology*, 23 (Suppl 1), 1-7. Nivå 2

**Sandvik RK, Selbaek G, Bergh S, Aarsland D, Husebo BS.**

Signs of Imminent Dying and Change in Symptom Intensity During Pharmacological Treatment in Dying Nursing Home Patients: A Prospective Trajectory Study. *Journal of the American Medical Directors Association*. Nivå 1

**Sandvik R, Selbaek G, Kirkevold O, Husebo BS, Aarsland, D.**

Analgesic prescribing patterns in Norwegian nursing homes from 2000 to 2001: trend analyses of four data samples. *Age and Ageing*, 45(1), 54-60. Nivå 1

**Selbæk G, Aarsland D, Ballard C, Engedal K, Langballe EM, Benth JŠ, Bergh S.**

Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients. *Journal of the American Medical Directors Association*, 17(5). 464. Nivå 1

**Svendsboe E, Terum T, Testad I, Aarsland D, Ulstein I, Corbett A, Rongve A.**

Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer's disease. *International journal of geriatric psychiatry*, 31(9), 1075-1083. Nivå 1

**Tajeddinn W, Fereshtehnejad SM, Seed Ahmed M, Yoshitake T, Kehr J, Shahnaz T, Milovanovic M, Behbahani H, Hoglund K, Winblad B, Cedazo-Minguez A, Jelic V, Jaremo P, Aarsland D.**

Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers. *Journal of Alzheimer's Disease*, 53(2), 621-630. Nivå 1

**Tajeddinn W, Persson T, Calvo-Garrido J, Seed Ahmed M, Maioli S, Vijayaraghavan S, Kazokoglu MS, Parrado-Fernandez C, Yoshitake T, Kehr J, Francis P, Winblad B, Hoglund K, Cedazo-Minguez A, Aarsland D.**

Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease. *Journal of Alzheimer's Disease*, 53(1), 349-361. Nivå 1

**Testad I, Mekki TE, Forland O, Oye C, Tveit EM, Jacobsen F, Kirkevold Ø.**

Modeling and evaluating evidence-based continuing education program in nursing home dementia care (MEDCED)-training of care home staff to reduce use of restraint in care home

residents with dementia. A cluster randomized controlled trial. *International journal of geriatric psychiatry*, 31(1), 24-32. Nivå 1

**Testad I, Meling M, Vagle V, Torsvik A, Frøiland CT, Kajander M, Gjestsen MT.**

Mestring og muligheter for personer med demens - 12-ukers kurs for personer med demens i tidlig fase. *Demens & alderspsykiatri*, 20(1), 30-32.

**van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW; European DLB consortium.**

Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. *Journal of Alzheimer's Disease*, 54(1), 287-95. Nivå 1

**Vijayaraghavan S, Darreh-Shori T, Rongve A, Berge G, Sando SB, White LR, Auestad BH, Witoelar A, Andreassen OA, Ulstein ID, Aarsland D.**

Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ε4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease. *Journal of Alzheimer's Disease*. [Epub ahead of print] Nivå 1

**Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Stevens T, Whitfield T, Aarsland D, Rainer M, Padovani A; DaTSCAN DLB Phase 4 Study Group.**

Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. *Neurology*, 87(10), 1045-1051. Nivå 2

**Xing H, Lim YA, Chong JR, Lee JH, Aarsland D, Ballard CG, Francis PT, Chen CP, Lai MK.**

Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias.

*Molecular Brain*, 9(1), 84. Nivå 1

**Oesterhus R, Aarsland D, Soennesyn H, Rongve A, Selbaek G, Kjosavik SR.**

Potentially inappropriate medications and drug–drug interactions in home-dwelling people with mild dementia. *International journal of geriatric psychiatry*. Nivå 1

**Aarsland D.**

Cognitive impairment in Parkinson's disease and dementia with Lewy bodies.

*Parkinsonism & Related Disorders*, 22(Suppl 1), 144-8. Nivå 1